🇺🇸 FDA
Pipeline program

Telisotuzumab Vedotin

M14-239

Phase 2 small_molecule active

Quick answer

Telisotuzumab Vedotin for Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials